Atomic emission method for total boron in blood during neutron-capture therapy

Juha Laakso (Corresponding Author), Martti Kulvik, Inkeri Ruokonen, Jyrki Vähätalo, Riitta Zilliacus, Markus Färkkilä, Merja Kallio

Research output: Contribution to journalArticleScientificpeer-review

44 Citations (Scopus)

Abstract

Background: Boron neutron-capture therapy (BNCT) is a drug-targeted binary radiotherapy for cancer. The 10B capture of thermal neutrons induces secondary radiation within cells during irradiation. The most widely used boron carrier is 4-dihydroxyborylphenylalanine (BPA). The duration and timing of the irradiation is adjusted by monitoring 10B concentrations in whole blood.

Methods: We developed a new method for boron determination that uses inductively coupled plasma atomic emission spectrometry (ICP-AES) and protein removal with trichloroacetic acid before analysis. This method was compared with the established but tedious inductively coupled plasma mass spectrometry (ICP-MS), which uses wet ashing as sample pretreatment. Erythrocyte boron concentrations were determined indirectly on the basis of plasma and whole blood boron concentrations and the hematocrit. The hematocrit was determined indirectly by measuring calcium concentrations in plasma and whole blood.

Results: Within- and between-day CVs were <5%. The recoveries for boron in whole blood were 95.6–96.2%. A strong correlation was found between results of the ICP-AES and ICP-MS (r = 0.994). Marked differences in plasma and erythrocyte boron concentrations were observed during and after infusion of BPA fructose complex.

Conclusions: The present method is feasible, accurate, and one of the fastest for boron determination during BNCT. Our results indicate that it is preferable to determine boron in plasma and in whole blood. Indirect erythrocyte-boron determination thus becomes possible and avoids the impact of preanalytical confounding factors, such as the influence of the hematocrit of the patient. Such an approach enables a more reliable estimation of the irradiation dose.
Original languageEnglish
Pages (from-to)1796-1803
Number of pages8
JournalClinical Chemistry
Volume47
Issue number10
Publication statusPublished - 2001
MoE publication typeA1 Journal article-refereed

Fingerprint

Neutron Capture Therapy
Boron
Neutrons
Blood
Hematocrit
Boron Neutron Capture Therapy
Erythrocytes
Plasmas
Inductively coupled plasma mass spectrometry
Irradiation
Inductively coupled plasma
Mass Spectrometry
Spectrum Analysis
Spectrometry
Trichloroacetic Acid
Fructose
Radiotherapy
Hot Temperature
Dosimetry

Cite this

Laakso, J., Kulvik, M., Ruokonen, I., Vähätalo, J., Zilliacus, R., Färkkilä, M., & Kallio, M. (2001). Atomic emission method for total boron in blood during neutron-capture therapy. Clinical Chemistry, 47(10), 1796-1803.
Laakso, Juha ; Kulvik, Martti ; Ruokonen, Inkeri ; Vähätalo, Jyrki ; Zilliacus, Riitta ; Färkkilä, Markus ; Kallio, Merja. / Atomic emission method for total boron in blood during neutron-capture therapy. In: Clinical Chemistry. 2001 ; Vol. 47, No. 10. pp. 1796-1803.
@article{4d0676bb8afa4b61859993e240b01409,
title = "Atomic emission method for total boron in blood during neutron-capture therapy",
abstract = "Background: Boron neutron-capture therapy (BNCT) is a drug-targeted binary radiotherapy for cancer. The 10B capture of thermal neutrons induces secondary radiation within cells during irradiation. The most widely used boron carrier is 4-dihydroxyborylphenylalanine (BPA). The duration and timing of the irradiation is adjusted by monitoring 10B concentrations in whole blood.Methods: We developed a new method for boron determination that uses inductively coupled plasma atomic emission spectrometry (ICP-AES) and protein removal with trichloroacetic acid before analysis. This method was compared with the established but tedious inductively coupled plasma mass spectrometry (ICP-MS), which uses wet ashing as sample pretreatment. Erythrocyte boron concentrations were determined indirectly on the basis of plasma and whole blood boron concentrations and the hematocrit. The hematocrit was determined indirectly by measuring calcium concentrations in plasma and whole blood.Results: Within- and between-day CVs were <5{\%}. The recoveries for boron in whole blood were 95.6–96.2{\%}. A strong correlation was found between results of the ICP-AES and ICP-MS (r = 0.994). Marked differences in plasma and erythrocyte boron concentrations were observed during and after infusion of BPA fructose complex.Conclusions: The present method is feasible, accurate, and one of the fastest for boron determination during BNCT. Our results indicate that it is preferable to determine boron in plasma and in whole blood. Indirect erythrocyte-boron determination thus becomes possible and avoids the impact of preanalytical confounding factors, such as the influence of the hematocrit of the patient. Such an approach enables a more reliable estimation of the irradiation dose.",
author = "Juha Laakso and Martti Kulvik and Inkeri Ruokonen and Jyrki V{\"a}h{\"a}talo and Riitta Zilliacus and Markus F{\"a}rkkil{\"a} and Merja Kallio",
year = "2001",
language = "English",
volume = "47",
pages = "1796--1803",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "10",

}

Laakso, J, Kulvik, M, Ruokonen, I, Vähätalo, J, Zilliacus, R, Färkkilä, M & Kallio, M 2001, 'Atomic emission method for total boron in blood during neutron-capture therapy', Clinical Chemistry, vol. 47, no. 10, pp. 1796-1803.

Atomic emission method for total boron in blood during neutron-capture therapy. / Laakso, Juha (Corresponding Author); Kulvik, Martti; Ruokonen, Inkeri; Vähätalo, Jyrki; Zilliacus, Riitta; Färkkilä, Markus; Kallio, Merja.

In: Clinical Chemistry, Vol. 47, No. 10, 2001, p. 1796-1803.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Atomic emission method for total boron in blood during neutron-capture therapy

AU - Laakso, Juha

AU - Kulvik, Martti

AU - Ruokonen, Inkeri

AU - Vähätalo, Jyrki

AU - Zilliacus, Riitta

AU - Färkkilä, Markus

AU - Kallio, Merja

PY - 2001

Y1 - 2001

N2 - Background: Boron neutron-capture therapy (BNCT) is a drug-targeted binary radiotherapy for cancer. The 10B capture of thermal neutrons induces secondary radiation within cells during irradiation. The most widely used boron carrier is 4-dihydroxyborylphenylalanine (BPA). The duration and timing of the irradiation is adjusted by monitoring 10B concentrations in whole blood.Methods: We developed a new method for boron determination that uses inductively coupled plasma atomic emission spectrometry (ICP-AES) and protein removal with trichloroacetic acid before analysis. This method was compared with the established but tedious inductively coupled plasma mass spectrometry (ICP-MS), which uses wet ashing as sample pretreatment. Erythrocyte boron concentrations were determined indirectly on the basis of plasma and whole blood boron concentrations and the hematocrit. The hematocrit was determined indirectly by measuring calcium concentrations in plasma and whole blood.Results: Within- and between-day CVs were <5%. The recoveries for boron in whole blood were 95.6–96.2%. A strong correlation was found between results of the ICP-AES and ICP-MS (r = 0.994). Marked differences in plasma and erythrocyte boron concentrations were observed during and after infusion of BPA fructose complex.Conclusions: The present method is feasible, accurate, and one of the fastest for boron determination during BNCT. Our results indicate that it is preferable to determine boron in plasma and in whole blood. Indirect erythrocyte-boron determination thus becomes possible and avoids the impact of preanalytical confounding factors, such as the influence of the hematocrit of the patient. Such an approach enables a more reliable estimation of the irradiation dose.

AB - Background: Boron neutron-capture therapy (BNCT) is a drug-targeted binary radiotherapy for cancer. The 10B capture of thermal neutrons induces secondary radiation within cells during irradiation. The most widely used boron carrier is 4-dihydroxyborylphenylalanine (BPA). The duration and timing of the irradiation is adjusted by monitoring 10B concentrations in whole blood.Methods: We developed a new method for boron determination that uses inductively coupled plasma atomic emission spectrometry (ICP-AES) and protein removal with trichloroacetic acid before analysis. This method was compared with the established but tedious inductively coupled plasma mass spectrometry (ICP-MS), which uses wet ashing as sample pretreatment. Erythrocyte boron concentrations were determined indirectly on the basis of plasma and whole blood boron concentrations and the hematocrit. The hematocrit was determined indirectly by measuring calcium concentrations in plasma and whole blood.Results: Within- and between-day CVs were <5%. The recoveries for boron in whole blood were 95.6–96.2%. A strong correlation was found between results of the ICP-AES and ICP-MS (r = 0.994). Marked differences in plasma and erythrocyte boron concentrations were observed during and after infusion of BPA fructose complex.Conclusions: The present method is feasible, accurate, and one of the fastest for boron determination during BNCT. Our results indicate that it is preferable to determine boron in plasma and in whole blood. Indirect erythrocyte-boron determination thus becomes possible and avoids the impact of preanalytical confounding factors, such as the influence of the hematocrit of the patient. Such an approach enables a more reliable estimation of the irradiation dose.

M3 - Article

VL - 47

SP - 1796

EP - 1803

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 10

ER -

Laakso J, Kulvik M, Ruokonen I, Vähätalo J, Zilliacus R, Färkkilä M et al. Atomic emission method for total boron in blood during neutron-capture therapy. Clinical Chemistry. 2001;47(10):1796-1803.